ADEXUSDx COVID-19 Test receives Conformité Européene (CE) mark approval
We are proud to announce that our ADEXUSDx COVID-19 antibody test has received Conformité Européene (CE) mark approval across 28 countries in the EU. With CE approval, our antibody test will be available in a variety of healthcare centers such as clinics and hospital emergency rooms.
Our ADEXUSDx COVID-19 Test is a rapid serology, self-contained assay that measures the presence of SARS-CoV-2 antibodies and delivers accurate and reliable results in 15 minutes with no buffers, reagents, or additional equipment.
Made in the USA, The ADEXUSDx® COVID-19 Test uses an FDA-cleared and CE-marked platform containing next-generation, easy-to-use technology that is affordable, portable, and delivers laboratory-quality results in minutes without any additional supplies.
Interested in learning more? You can read the full article here.
NOWDiagnostics, Inc., based in Springdale, Arkansas, is a leader in innovative diagnostics testing. Its ADEXUSDx® product line features a lab at your fingertip, using a single drop of blood to test for a variety of common conditions, illnesses, and diseases, with results in a matter of minutes. By eliminating the need to send tests to off-site laboratories, NOWDiagnostics products have the potential to decrease the waiting period to determine test results by days. For more information about NOWDiagnostics, visit www.nowdx.com. For more information about the ADEXUSDx® COVID-19 Test, including its intended use, features, benefits and limitations, and directions for use, visit www.c19development.com. The ADEXUSDx® COVID-19 Test will be distributed by C19 Development, LLC, a wholly owned subsidiary of NOWDiagnostics. Laboratories may contact www.c19development.com/order to place an order.
NOWDiagnostics Company Contact
Beth Cobb, Director of Operations
NOWDiagnostics Media Contact
Claire Burghoff, CGA Group